Clinical Trial Update: Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Iparomlimab and Tuvonralimab with nab-paclitaxel as neoadjuvant therapy for locally advanced resectable esophageal s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: ESCC | Phase 2 | Status: NOT_YET_RECRUITING